Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mei Yi Sim"'
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178168 (2017)
The dioxonapthoimidazolium YM155 is a survivin suppressant which has been investigated as an anticancer agent in clinical trials. Here, we investigated its growth inhibitory properties on a panel of immortalized and patient derived renal cell carcino
Externí odkaz:
https://doaj.org/article/a23f33d3bd1c43fcadfde7947ebc518c
Autor:
Mei Yi Sim, Jean Xiang Ying Sim, Hong Hong Huang, Dorothy Hui Lin Ng, Jay Kheng Sit Lim, Jenny G. Low
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases
s Easy access to screening for timely identification and isolation of infectious COVID-19 patients remains crucial in sustaining the international efforts to control COVID-19 spread. A major barrier limiting broad-based screening is the lack of a sim
Publikováno v:
Life Sciences. 203:282-290
Aim To investigate the effect of dioxonaphthoimidazolium analog YM155 on cell cycle progression of the clear-cell variant of renal cell carcinoma (ccRCC). Main methods Cell cycle analysis was performed using bromodeoxyuridine (BrdU) and PI, apoptosis
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
Constitutive activation of the NF-κB signaling cascade is associated with tumourigenesis and poor prognosis in many human cancers including RCC. YM155, a small molecule inhibitor of survivin, was previously shown to potently inhibit the viability of
Autor:
Daw Aye Aye Thike, Tsung Wen Chong, Mei Yi Sim, Bin Tean Teh, Weng Khong Lim, Puay Hoon Tan, Hong Hong Huang, Fera Yiqian Goh
Publikováno v:
Journal of Clinical Pathology
Aims We hypothesised that CD1d expression in renal cell carcinoma (RCC) may play a role in modifying the host immune response. Our aims were to investigate the expression of CD1d and to correlate this with histopathology and clinical outcomes in a co
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178168 (2017)
PLoS ONE
PLoS ONE
The dioxonapthoimidazolium YM155 is a survivin suppressant which has been investigated as an anticancer agent in clinical trials. Here, we investigated its growth inhibitory properties on a panel of immortalized and patient derived renal cell carcino
Autor:
Tsung Wen Chong, Richard Weijie Ong, Mei Yi Sim, John Shyi Peng Yuen, Christopher Cheng, Weber Kam On Lau, Hong Gee Sim, Hung Huynh
Publikováno v:
International Journal of Oncology. 41:712-720
Sorafenib, a multikinase inhibitor, is currently used as monotherapy for advanced renal cell carcinoma (RCC). However, adverse effects associated with its use have been experienced by some patients. In this study, we examined the antitumor and antian
Autor:
Tsung Wen Chong, Fera Yiqian Goh, Mei Yi Sim, Hong Hong Huang, Daw Aye Aye Thike, Weng Khong Lim, Bin Tean Teh, Puay Hoon Tan
Publikováno v:
Journal of Clinical Pathology; Mar2015, Vol. 68 Issue 3, p200-205, 6p